Abstract
AbstractKnowledge gaps regarding human immunity toStreptococcus pyogeneshave impeded vaccine development. To address these gaps and evaluate vaccine candidates, we established a human challenge model ofS. pyogenespharyngitis. Here, we analysed antibody responses in serum and saliva against 19 antigens to identify characteristics distinguishing 19 participants who developed pharyngitis and 6 who did not. Pharyngitis elicited serum IgG responses to key vaccine antigens and a muted mucosal IgA response, whereas the 6 participants without pharyngitis had more pronounced IgA responses and minimal IgG responses. Serum IgG responses to pharyngitis in adult participants resembled those observed in children and were inversely correlated with the magnitude of pre-existing responses. While a straightforward correlate of protection was not evident, baseline antibody signatures distinguished clinical and immunological outcomes following experimental challenge. This highlights the influence of a complex humoral imprint from previous exposure, relevant for interpreting immunogenicity in forthcoming vaccine trials.
Publisher
Cold Spring Harbor Laboratory
Reference71 articles.
1. Pathogenesis, epidemiology and control of Group A Streptococcus infection
2. Global Burden of Cardiovascular Diseases and Risk Factors, 1990–2019
3. Group A Streptococcal Diseases and Their Global Burden
4. Immunization VaB, Vaccine Prioritization & Platforms Team. Strategic Priority 7: Regional engagement strategy to identify IA2030 global priority endemic pathogens. Product Development for Vaccines Advisory Committee (PDVAC) Meeting, World Health Organization. (https://www.who.int/news-room/events/detail/2023/12/12/default-calendar/2023-meeting-who-product-development-for-vaccines-advisory-committee-meeting-pdvac).
5. WHO/IVI global stakeholder consultation on group A Streptococcus vaccine development: Report from a meeting held on 12–13 December 2016